AI-Driven Drug Discovery: Isomorphic Labs Strategy
Isomorphic Labs President Max Jodberg discusses leveraging AI to shift drug discovery from empirical trial-and-error to predictive simulation. The analysis covers the economic inefficiencies of traditional biopharma, the strategic value of proprietary data generation, and the potential for AI to reduce clinical failure rates and accelerate therapeutic development.